Cambrex Corporation Overview
Pro stress-test →Cambrex Corporation is a leading provider of contract development and manufacturing services for the pharmaceutical and biotechnology sectors. The company generated annual revenue of $717.6 million in 2026 and serves as a critical infrastructure provider supporting drug development and manufacturing across the pharmaceutical industry's full product lifecycle.
Strategic Profile
Pro stress-test →The company is expanding its operational footprint across the United States and Europe to meet rising global demand for high-quality drug development and manufacturing solutions, while enhancing its ability to support customers throughout the entire product lifecycle. Cambrex specializes in complex small molecule development projects and active pharmaceutical ingredient (API) manufacturing.
Competitive Landscape
Pro stress-test →Cambrex competes with firms including Theorem Clinical Research, Recipharm, CordenPharma, Catalent, and Actylis in the CDMO market. The company differentiates through geographic diversification, specialized API capabilities, and integrated drug development services spanning small molecules to peptides.
Industry Context
Cambrex Corporation operates in Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Services.
Key facts
Headquarters: East Rutherford, New Jersey · Employees: 1,744 · Revenue: $717.6M